Pricing Availability   Qty
Description: Selective μ agonist
Alternative Names: DAGO
Chemical Name: [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin
Purity: ≥95% (HPLC)
Citations (37)
Reviews (1)
Literature (2)

Biological Activity for DAMGO

DAMGO is a highly selective peptide agonist for the μ opioid receptor.

Technical Data for DAMGO

M. Wt 513.7
Formula C26H35N5O6
Sequence YAGFG

(Modifications: Ala-2 = D-Ala, Phe-4 = N-methyl-Phe, Gly-5 = Gly-ol)

Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 78123-71-4
PubChem ID 5462471
Smiles [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC1=CC=CC=C1)C(=O)NCCO

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for DAMGO

Solubility Soluble to 2 mg/ml in water

Product Datasheets for DAMGO

Certificate of Analysis / Product Datasheet
Select another batch:

References for DAMGO

References are publications that support the biological activity of the product.

Fang et al (1989) Opioid receptors (DAGO-enkephalin, dynorphin A(1-13), BAM 22P) microinjected into the rat brainstem: comparison of their antinociceptive effect and their effect on neuronal firing in the rostral ventromedial medulla. Brain Res. 501 116 PMID: 2572306

Hirning et al (1985) Studies in vitro with ICI 174,864, [D-Pen2,D-Pen5]-enkephalin (DPDPE) and [D-Ala2,NMePhe4,Gly-ol]-enkephalin (DAGO). Neuropeptides 5 383 PMID: 2987739

If you know of a relevant reference for DAMGO, please let us know.

View Related Products by Product Action

View all μ Opioid Receptor Agonists

Keywords: DAMGO, DAMGO supplier, Selective, μ-opioid, mu-opioid, agonist, MOP, Receptors, OP3, DAGO, Mu, Opioid, 1171, Tocris Bioscience

37 Citations for DAMGO

Citations are publications that use Tocris products. Selected citations for DAMGO include:

Gruol et al (2012) Ethanol alters opioid regulation of Ca(2+) influx through L-type Ca(2+) channels in PC12 cells. Alcohol Clin Exp Res 36 443 PMID: 22014285

Nassirpour et al (2010) Morphine- and CaMKII-dependent enhancement of GIRK channel signaling in hippocampal neurons. J Neurosci 30 13419 PMID: 20926668

Wang et al (2010) Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci U S A 107 13117 PMID: 20615975

Maione et al (2009) Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia. J Neurophysiol 101 2411 PMID: 19297510

Chen et al (2014) μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain. Neuroscience 267 67 PMID: 24583035

Bao et al (2018) Clinical opioids differentially induce co-internalization of μ- and δ-opioid receptors. Mol Pain 14 1744806918769490 PMID: 29587571

Dai et al (2018) Selective blockade of spinal D2DR by levo-corydalmine attenuates MOR tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner. Exp Mol Med 50 148 PMID: 30429454

Dziedowiec et al (2018) sMu opioid receptor agonist DAMGO produces place conditioning, abstinence-induced withdrawal, and naltrexone-dependent locomotor activation in planarians. Neuroscience 386 214 PMID: 29958944

Reyes et al (2012) Opiate agonist-induced re-distribution of Wntless, a mu-opioid receptor interacting protein, in rat striatal neurons. Exp Neurol 233 205 PMID: 22001156

Lorier et al (2010) Opiate-induced suppression of rat hypoglossal motoneuron activity and its reversal by ampakine therapy. PLoS One 5 e8766 PMID: 20098731

Hull et al (2010) The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther 332 1127 PMID: 20008489

Brewer et al (2014) DA D3 receptor dysfunction prevents anti-nociceptive effects of mor. in the spinal cord. Front Neural Circuits 8 62 PMID: 24966815

Beaudry et al (2011) Activation of spinal mu- and δ-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. Neurochem Res 31 13068 PMID: 21917790

Lee et al (2011) Differential pharmacological actions of meth. and Bupren. in human embryonic kidney 293 cells coexpressing human μ-opioid and opioid receptor-like 1 receptors. Br J Pharmacol 36 2008 PMID: 21671107

Mamaligas et al (2016) Nicotinic and opioid receptor regulation of striatal DA D2-receptor mediated transmission Scientific Reports 6 37834 PMID: 27886263

Beaudry et al (2015) Regulation of μ and δ opioid receptor functions: involvement of cyclin-dependent kinase 5. Invest Ophthalmol Vis Sci 172 2573 PMID: 25598508

Wang et al (2015) Bupren.-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors. PLoS One 19 2587 PMID: 26153065

Bai et al (2015) Sex differences in peripheral mu-opioid receptor mediated analgesia in rat orofacial persistent pain model. J Neurosci 10 e0122924 PMID: 25807259

Taylor et al (2015) Microglia disrupt mesolimbic reward circuitry in chronic pain. Br J Pharmacol 35 8442 PMID: 26041913

Ong et al (2015) Prolonged mor. treatment alters δ opioid receptor post-internalization trafficking. J Neurosci 172 615 PMID: 24819092

Kokkola et al (2005) S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner. BMC Cell Biol 6 21 PMID: 15850493

Schmid et al (2017) Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell 171 1165 PMID: 29149605

Krook-Magnuson et al (2011) Ivy and neurogliaform interneurons are a major target of μ-opioid receptor modulation. J Neurosci 31 14861 PMID: 22016519

Akoume et al (2019) A Differential Hypofunctionality of Gαi Proteins Occurs in Adolescent Idiopathic Scoliosis and Correlates with the Risk of Disease Progression. Sci Rep 9 10074 PMID: 31296888

Ford (2017) Characterization of structurally novel G protein biased CB1 agonists: implications for drug development. Pharmacol Res 125 161 PMID: 28838808

Morse et al (2011) Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS One 6 e25643 PMID: 22003401

Nam et al (2019) Activation of Astrocytic μ-Opioid Receptor Causes Conditioned Place Preference Cell Rep 28 1154 PMID: 31365861

Nasrallah et al (2019) Routing Hippocampal Information Flow through Parvalbumin Interneuron Plasticity in Area CA2. Cell Rep 27 86 PMID: 30943417

Montandon (2017) δ-subunit containing GABAA receptors modulate respiratory networks. Sci Rep 7 18105 PMID: 29273726

Ye (2017) Alterations in opioid inhibition cause widespread nociception but do not affect anxiety-like behavior in oral cancer mice. Neuroscience 363 50 PMID: 28673713

Garzón et al (2009) Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with mor. Mol Pain 5 11 PMID: 19284549

Liu et al (2015) Morphological and physiological evidence of a synaptic connection between the lateral parabrachial nucleus and neurons in the A7 catecholamine cell group in rats. J Biomed Sci 22 79 PMID: 26385355

Zhou et al (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288 36703 PMID: 24187130

Vicente-Sánchez et al (2013) HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity. Mol Brain 6 42 PMID: 24093505

Rajasekaran et al (2013) Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269 100 PMID: 23537664

Kharmate et al (2013) Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells. Cancer Cell Int 13 93 PMID: 24059654

Morse et al (2013) Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family. BMC Pharmacol Toxicol 14 17 PMID: 23497702

Do you know of a great paper that uses DAMGO from Tocris? Please let us know.

Reviews for DAMGO

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used DAMGO?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

DAMGO current in spinal dorsal horn neuron.
By Allen Dickie on 03/24/2023
Assay Type: Ex Vivo
Species: Mouse

Whole cell patch clamp recording (voltage clamp) from spinal dorsal horn interneuron, in ex vivo slice preparation, in response to bath application of DAMGO (3 µM), in the presence of TTX, bicuculline and strychnine.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Peptides Involved in Appetite Modulation Scientific Review

Peptides Involved in Appetite Modulation Scientific Review

Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.